Literature DB >> 35654291

Helicobacter pylori infection induces stem cell-like properties in Correa cascade of gastric cancer.

JunJian He1, WeiChao Hu1, Qin Ouyang2, ShengWei Zhang1, LiJiao He1, WeiYan Chen1, XinZhe Li3, ChangJiang Hu4.   

Abstract

Gastric cancer (GC) is the fourth leading cause of cancer-related death. Its poor prognosis is attributed to unclear pathogenesis. Currently, the most widely accepted model for elucidating the mechanism of GC is the Correa cascade, which covers several histological lesions of the gastric mucosa. GC stem cells (CSCs) are crucial for oncogenesis in the Correa cascade and GC progression. As Helicobacter pylori (H. pylori) is the etiological factor in the Correa cascade, growing evidence suggests that enhancement of gastric stem cell-like properties and increase in CSCs correlate with H. pylori infection. In this paper, we review recent studies that present pathogenic mechanisms by which H. pylori induces gastric stem cell-like properties and CSCs, which may supplement the existing Correa model of GC. First, the dysfunction of developmental signaling pathways associated with H. pylori infection leads to the enhancement of gastric stemness. Second, H. pylori infection promotes alteration of the gastric mucosal microenvironment. In addition, epithelial-mesenchymal transition (EMT) may contribute to H. pylori-induced gastric stemness. Taken together, understanding these pathogeneses will provide potential therapeutic targets for the treatment of CSCs and malignant GC in H. pylori induced-Correa cascade of GC.
Copyright © 2022 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cancer stem cell; Epithelial–mesenchymal transition; Microenvironment remodeling

Mesh:

Year:  2022        PMID: 35654291     DOI: 10.1016/j.canlet.2022.215764

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   9.756


  1 in total

Review 1.  Therapeutic strategies for gastric cancer targeting immune cells: Future directions.

Authors:  Yan Zhao; Yuansong Bai; Meili Shen; Yapeng Li
Journal:  Front Immunol       Date:  2022-09-23       Impact factor: 8.786

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.